Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR
β Scribed by Mu-Chin Shih; Kun-Tu Yeh; Kai-Ping Tang; Jui-Chang Chen; Jan-Gowth Chang
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 443 KB
- Volume
- 45
- Category
- Article
- ISSN
- 0899-1987
- DOI
- 10.1002/mc.20198
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Methylation of CpG dinucleotides in the promoter sequence of a gene can lead to deregulated and suppressed gene expression. In this study, we have developed procedures for methylationβspecific polymerase chain reaction (MSP) and sequencing analysis to determine CpG methylation status of the promoter sequences of nine circadian genes in 35 endometrial cancers (EC) and paired noncancerous endometrial tissues. DNA methylation was found in the promoter sequences of PER1, PER2, and CRY1, but not of other six circadian genes in the ECs and normal tissues examined. Eleven of the 35 EC tissues showed CpG methylation in the promoter sequences of PER1, PER2, or CRY1. Of these 11 cases, 1 had promoter methylation in all the three genes, 1 in PER1 and PER2, 3 in PER1 and CRY1, and 6 in PER1, respectively. In comparison, promoter CpG methylation of PER1, PER2, or CRY1 was found in only 7 of 35 paired noncancerous tissues including 2 in PER1 and PER2, 2 in PER1, and 3 in CRY1. In summary, promoter methylation in the PER1, PER2, or CRY1 circadian genes was detected in about oneβthird of EC and oneβfifth of noncancerous endometrial tissues of 35 paired specimens indicating possible disruption of the circadian clock in the development of EC. Β© 2006 WileyβLiss, Inc.
π SIMILAR VOLUMES
## Abstract Loss of DNA mismatch repair occurs in a variety of malignancies and is associated with genomeβwide instability of microsatellite repeats, a molecular phenotype referred to as microsatellite instability (MSI). MSI is a consistent feature of colorectal and endometrial tumors from patients
## Abstract Tumor suppressor genes (TSGs) are sometimes inactivated by transcriptional silencing through promoter hypermethylation. To identify novel methylated TSGs in melanoma, we carried out global mRNA expression profiling on a panel of 12 melanoma cell lines treated with a combination of 5βAza
The enzyme O 6 -methylguanine-DNA methyltransferase (MGMT) protects cells from the cytotoxic and mutagenic effects of alkylating agents. Approximately 20% of tumor cell lines lack MGMT activity and are highly sensitive to alkylating agents. In established cancer cell lines, MGMT expression appears t